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Axitinib is an oral angiogenesis inhibitor, currently approved for treatment of metastatic
renal cell carcinoma (mRCC) after failure of prior treatment with Sunitinib or cytokine.
The present study is an Italian Multi-Institutional Retrospective Analysis that evaluated
the outcomes of Axitinib, in second-line treatment of mRCC. The medical records of
62 patients treated with Axitinib, were retrospectively reviewed. The Progression Free
Survival (PFS), the Overall Survival (OS), the Objective Response Rate (ORR), the Disease
Control Rate (DCR), and the safety profile of axitinib and sunitinib–axitinib sequence, were
the primary endpoint. The mPFS was 5.83 months (95% CI 3.93–7.73 months). When
patients was stratified by Heng score, mPFS was 5.73, 5.83, 10.03 months according
to poor, intermediate, and favorable risk group, respectively. The mOS from the start of
axitinib was 13.3 months (95% CI 8.6–17.9 months); the observed ORR and DCR were
25 and 71%, respectively. When stratified patients by subgroups defined by duration of
prior therapy with Sunitinib (≤ vs. >median duration), there was a statistically significant
difference in mPFS with 8.9 (95% CI 4.39–13.40 months) vs. 5.46 months (95% CI
4.04–6.88 months) for patients with a median duration of Sunitinib >13.2 months.
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DCR and ORR to previous Sunitinib treatment was associated with longer statistically
mPFS, 7.23 (95%CI 3.95–10.51months, p= 0.01) and 8.67 (95%CI 4.0–13.33months,
p = 0.008) vs. 2.97 (95% CI 0.65–5.27 months, p = 0.01) and 2.97 months (95%
CI 0.66–5.28 months, p = 0.01), respectively. Overall Axitinib at standard schedule of
5mg bid, was well-tolerated. The most common adverse events of all grades were fatig
(25.6%), hypertension (22.6%), gastro-intestinal disorders (25.9%), and hypothyroidism
(16.1%). The sequence Sunitinib–Axitinib was well-tolerated without worsening in side
effects, with a median OS of 34.7 months (95% CI 18.4–51.0 months). Our results are
consistent with the available literature; this retrospective analysis confirms that Axitinib is
effective and safe in routine clinical practice.
Keywords: mRCC, first-line treatment, axitinib, real-life patient, mPFS
INTRODUCTION
Renal Cell Carcinoma (RCC) accounts for 2–3% of all adult
malignancies, representing the seventh most common cancer in
men and the ninth most common cancer in women (Escudier
et al., 2013). Its incidence has increased over the past several
years, contributing to increasing mortality rate. RCC is a family
of tumors, each with distinct genetic landscapes, different growth
patterns, and metastatic potentials, resulting in a heterogeneous
group of disease processes (Linehan et al., 2013). Clear cell renal
cell carcinoma (ccRCC) is the most common RCC (75–80% of
all primary kidney malignancies; Cohen and McGovern, 2005).
Approximately 25–30% of patients with kidney cancer present
metastases at the time of diagnosis and ∼30% develop recurrent
or metastatic disease after radical treatment for localized disease
(Leung et al., 2014). Recurrent and/or metastatic renal cell
carcinoma (mRCC) is associated with a poor 5-years survival,
roughly 10%, however, in the last decade, a series of novel
agents have been introduced in clinical practice and the outcomes
are slowly improving. Angiogenesis plays a central role in
the development, growth, and metastatic progression of RCC
via VHL, HIF 1α, VEGF, PDGF, mTOR (PI3K/AKT signaling;
Nicol et al., 1997; Dorevic´ et al., 2009; Kornakiewicz et al.,
2013; Dimova et al., 2014). Despite an increasing knowledge
about the genetic and signaling abnormalities involved in
the RCC carcinogenesis, such as VHL, PBRM1, SETD2, and
BAP1, no biomarkers are currently available thus there are no
molecular factors which may guide the clinicians in choosing
the therapeutic strategy (Brugarolas, 2014; D’Aniello et al., 2014;
Cavaliere et al., 2015). The advent of the Target Therapies (TTs)
has revolutionized the mRCC treatment with an impressive effect
on the Overall Survival (OS), which increased from an average
of 9 months in 1995, when the only option in first line was
interferon-alfa (IFN-α), to a median of 28–29 months in 2013,
the TTs era (Motzer and Russo, 2000; Chowdhury et al., 2008;
Albiges et al., 2015; de Velasco et al., 2015). The TTs include
the Tyrosine Kinase Inhibitors, TKIs, targeting the Vascular
Endothelial Growth Factor Receptors, VEGFRs, the mammalian
Target of Rapamycin inhibitors, mTORis, and Bevacizumab, a
monoclonal antibody targeting the VEGF ligand.
Axitinib, a potent oral and selective TKi of VEGFR-1, VEGFR-
2, and VEGFR-3, has been recently approved in second line after
sunitinib or cytokines failure. The second-line phase III AXIS
trials compared axitinib, 5mg twice daily dose-titrated up or
down to tolerance, with sorafenib in patients who progressed
despite first-line therapy containing sunitinib, bevacizumab plus
IFN-α, temsirolimus, or cytokines. The median Progression
Free Survival (mPFS), primary endpoint, was 6.7 months with
axitinib compared to 4.7 months with sorafenib (HR: 0.665;
95% CI 0.544–0.812; one-sided p < 0.0001) regardless of prior
treatment. Partial responses were seen more often after Axitinib
than Sorafenib (19.4 vs. 9.4%, p < 0.001). In patients previously
treated with Sunitinib, mPFS was 4.8 months in Axitinib arm
and 3.4 months in Sorafenib arm (p = 0.011; Rini et al., 2011).
In a recent update, the mOS was 20.1 (95% CI 16.7–23.4)
with Axitinib and 19.2 months (17.5–22.3) with Sorafenib (HR:
0.969, 95% CI 0.800–1.174; one-sided p = 0.3744; Hutson et al.,
2013; Motzer et al., 2013). The most common adverse events
were diarrhea, hypertension, and fatig. To date, according to
National Cancer Guidelines, Axitinib, Everolimus, and Sorafenib
are registered in second-line treatment of mRCC. Evidences
from randomized clinical trials, retrospective studies or single-
institution experiences do not provide clear and conclusive
information whichmight guide the clinician in choosing Axitinib
rather than Everolimus than Sorafenib, or vice versa, in the
second-line setting, hence the decision is made exclusively on the
basis of the safety profile and patients medical history. Several
“real world” studies have showed the efficacy and safety of Axitinb
in unselected populations (Vogl et al., 2013; Basso et al., 2014;
Maroto et al., 2014; Matias et al., 2014; Signorovitch et al., 2015;
Vogelzang et al., 2015, 2016; Guida et al., 2016; Hutson et al.,
2016; Laskey et al., 2016; Pal et al., 2016; Wagstaff et al., 2016), we
thought to further reinforce such evidences publishing our own
experience with the drug.
PATIENTS AND METHODS
This is a multi-institutional, observational, retrospective study
(SAX), which was carried out in nine Italian Oncology Centers,
after approval by the National Cancer Institute of Naples
Institutional Board. Medical records of patients who were treated
with axitinib, in second line, between January 2014 and January
2016 were retrospectively reviewed. All subjects gave written
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informed consent in accordance with the Declaration of Helsinki.
To be eligible, patients were required to meet the following
inclusion criteria: aged ≥18 years, histologically confirmed RCC,
treatment with Axitinib started between January 2014 and
January 2016 with at least one radiological reassessment of
disease, radiologically measurable disease according to RECIST
1.1 criteria, first line treatment with Sunitinib at least 2 months of
therapy.We administered Axitinib according to the conventional
and dose-titration schedule.
The primary endpoint was Progression Free Survival, PFS,
Overall Survival, OS, Objective Response Rate, ORR, Disease
Control Rate, DCR, and the safety profile of Axitinib and
Sunitinib–Axitinib sequence. The secondary objectives included
the potential relationships between Patient’s demographics and
baseline characteristics, AEs and response to treatment. PFS was
defined as the interval between the date of the first dose of
Axitinib and the date of the disease progression or death from
any cause; disease progression was defined as radiological tumor
progression according to Response Evaluation Criteria In Solid
Tumors, RECIST, version 1.1, or clinical progression, including
death. AEs were graded according to Common Terminology
Criteria for Adverse Events version 4.0.
Descriptive statistics were used to describe Patient’s
demographics and baseline characteristics, treatment patterns
and Adverse Events, AEs. Categorical variables are described
by patient counts and percentages. The univariate risks of
progression and death were examined: PFS by treatment line of
therapy and OS curves were estimated by the Kaplan–Meier and
selected variables were compared using two-sided log-rank test.
The Cox proportional hazards model was fitted to estimate the
risk of progression or of death; hazard ratio (HR) and 95% CI
was estimated, adjusted for age, gender, and center. The SPSS
statistical package version 23.0 (SPSS Inc., Chicago, IL) was used
for all statistical analysis.
RESULTS
Between Jan 2014 and Jan 2016, 62 patients with mRCC or
recurrent RCC were eligible for the final analysis.
Patient’s demographics and baseline characteristics were
summarized in Table 1. Median age was 62 years old,
most patients were male (88.7%), the 67.7% had an ECOG
Performance Score of 0. Of the 62 patients, 54 (87.1%) had prior
nephrectomy and only 4.8% (3/62) had a histological diagnosis
different from clear cell. Lung was the first site of metastasis
(47.8%) and 6.5% (4/62) of patients had liver metastasis. Based
on the MSKCC score classification, only 6.5% (4/62) patients
were “poor risk,” themost being “intermediate” 69.4% and “good”
24.2%, while according to Heng score, 12.9% (8/62) patients were
“poor risk,” 67.7 and 19.4% were intermediate and favorable risk,
respectively.
Clinical Outcomes
The mPFS was 5.83 months (95% CI 3.93–7.73 months;
Figure 1). The mOS from the start of Axitinib, was 13.3 months
(95% CI 8.6–17.9 months; Figure 2). The ORR, according to
RECIST criteria version 1.1 (Eisenhauer et al., 2009) was 25%,
TABLE 1 | Baseline demographic and clinical patients’ characteristics.
Baseline characteristics N (%)
Median age years (range) 62 (36–86)
Age
≤65 39 (62.9%)
>65 23 (37.1%)
Gender
Male 55 (88.7%)
Female 7 (11.3%)
ECOG PS
0 42 (67.7%)
1 18 (29.0%)
2 2 (3.2%)
Prior nephrectomy
Yes 54 (87.1%)
No 8 (12.9%)
MOTZER score
Poor 4 (6.5%)
Intermediate 43 (69.4%)
Favorable 15 (24.2%)
HENG score
Poor 8 (12.9%)
Intermediate 42 (67.7%)
Favorable 12 (19.4%)
Site of disease
Lung 29 (47.8%)
Bone 8 (12.9%)
Liver 4 (6.5%)
Lymph node 9 (14.5%)
Other 12 (19.4%)
with the 23% of patients achieving a Partial Response, PR, and
one patient having a Complete Response, CR (Figure 3). The
DCR to Axitinib was 71% and correlated with longer statistically
mPFS, 9.33 (95% CI 5.51–13.15 months, p < 0.001) vs. 3.26
months (95% CI 2.98–3.54 months, p < 0.001), respectively.
DCR and ORR to previous Sunitinib treatment was associated
with longer statistically mPFS, 7.23 (95% CI 3.95–10.51 months,
p = 0.01) and 8.67 (95% CI 4.0–13.33 months, p = 0.008) vs.
2.97 (95% CI 0.65–5.27 months, p= 0.01) and 2.97 months (95%
CI 0.66–5.28 months, p = 0.01), respectively (Table 2). mOS
was not reached for ORR (RC+RP), the mean OS according
to DCR and ORR was 14.95 (95% CI 12.4–17.49 months,
p = 0.056) and 15.66 (95% CI 12.19–19.10 months, p =
0.057) vs. 7.4 (95% CI 3.85–11.0 months, p = 0.056) and 7.42
(95% CI 3.81–11.02 months, p = 0.057), respectively (Table 2).
When stratified patients by subgroups defined by duration
of prior therapy with Sunitinib (≤ vs. >median duration),
there was a statistically significant difference in mPFS with 8.9
(95% CI 4.39–13.40 months, p = 0.03) vs. 5.46 months (95%
CI 4.04–6.88 months, p = 0.03) for patients with a median
duration of Sunitinib >13.2 months without differences in mOS
(p = 0.27; Table 2). No differences in terms of mPFS according
to type of sunitinib-schedule (standard schedule vs. modified
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FIGURE 1 | Kaplan–Meier curve of median PFS of the patients under study.
FIGURE 2 | Kaplan–Meier curve of median OS of the patients under study from the start of axitinib.
schedule; p = 0.6; Table 2). When patients was stratified by
Heng score mPFS was 5.73, 5.83, 10.03 months according to
poor, intermediate and favorable risk group, respectively. The
same results was achieved when used Motzer score, but only
Heng score stratification correlated statistically significantly with
OS (p = 0.02; Table 2). There was no statistically significant
difference in mPFS and mOS when stratified patients according
to ECOG Performance Status (p = 0.8 and 0.7, respectively;
Table 2). Prior nephrectomy correlated with longer statistically
mPFS, 6.30 (95% CI 2.77–9.82 months, p= 0.01) vs. 3.03 months
(95% CI 2.86–3.20 months, p = 0.01), respectively and also with
longer statistically mOS (p = 0.003; Table 2), even if the median
OS was not reached. Overall Axitinib at standard schedule of
5mg bid, was well-tolerated, with no grade 4 toxicity. Dose
reduction occurred in 21% (13/62) of which five patients in
the titration group. The most common adverse events of all
grades were fatig (25.6%) hypertension (22.6%), gastro-intestinal
disorders (25.9%), hypothyroidism (16.1%), hand-foot syndrome
(8.1%), we observed no cases of dysphonia (Table 3). According
to AEs recorded, we did not find predictor of better outcome.
The sequence Sunitinib–Axitinib was well-tolerated without
worsening in side effects, particularly in terms of hypertension
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FIGURE 3 | Kaplan–Meier curve of overall median OS of the patients under study, sunitinib–axitinib sequence.
TABLE 2 | Univariate analysis of mPFS and mOS in our study population.
p-value
mPFS mOS
Tumor response rate to prior sunitinib
DCR 0.01 0.056
ORR 0.008 0.057
Duration of prior sunitinib treatment
≤13.2 vs. >13.2 months 0.03 0.27
Heng score 0.3 0.02
ECOG PS 0.8 0.7
Prior nefrectomy 0.01 0.003
and hand–foot syndrome, with a mOS for the overall analysis
population of 34.7 months (95% CI 18.4–51.0 months; Figure 4).
Table 4 summarized the adjusted hazard ratios for PFS and
OS according to prior nephrectomy, duration, ORR, and DCR
of prior treatment with Sunitinib. The multivariate model was
adjusted for age, gender, and center. Prior nephrectomy andDCR
showed a significant independent impact either for PFS (HR:
0.32; 95% CI 0.13–0.78, p = 0.01; HR: 0.35; 95% CI 0.15–0.81,
p = 0.01, respectively), and for OS (HR: 0.24; 95% CI 0.08–0.68,
p = 0.007; HR: 0.36; 95% CI 0.13–0.98, p = 0.047, respectively).
Duration of prior treatment (>13 months) and ORR showed
a significant independent role only in the PFS (HR: 0.48; 95%
CI 0.25–0.94, p = 0.03; HR: 0.28; 95% CI 0.10–0.77, p = 0.01,
respectively).
Outcome in Dose Titration Axitinib
Dose escalation to 7 or 10mg bid was feasible in 15 patients
(24.2%). mPFS was longer, but not statistically significant, than
TABLE 3 | Adverse events of axitinib in our study population.
AE Axitinib titration
All grades ≥Grade 3 All grades ≥Grade 3
(n = 62) (n = 62) (n = 15) (n = 15)
N (%) N (%)
Hematologic 2 (3.3) – – –
Hypertension 11 (18) 3 (4.9) 2 (13.3) 1 (6.7)
Gastro-intestinal 9 (14.5) 3 (4.8) 2 (13.3) –
Hypothyroidism 10 (16.1) – 3(20) –
Fatig 11 (17.7) 5(8.1) 3(20) 1 (6.7)
Hepatic 1 (1.6) – – –
Hand–foot syndrome 4 (6.5) 1 (1.6) 2(13.3) 1(6.7)
Dysphonia – – 2(13.3) –
patients without dose titration, 10.03 (95% CI 2.05–18.015
months, p = 0.07) vs. 5.63 months (95% CI 4.92–6.34 months,
p= 0.07), respectively (Table 2). mOSwas not significant for dose
titration too (p= 0.09, Table 2). Dose titration was well-tolerated
with only increase in the incidence of hypothyroidism and fatig,
no worsening of hypertension (Table 3).
DISCUSSION
The development of TTs, VEGFR-TKi, and mTORi, resulted in a
significant improvement in terms of both PFS and OS. However,
resistance to drugs will occur in most patients. A reasonable
approach to overcome drug resistance is the use of sequential
therapy, and some drugs that showed efficacy in the second-line
setting are in use. The optimization of the disease management
should be based on clinical trials but also on real experiences,
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also known as “real world” or “real life” studies, which are more
reproducible compared with randomized trials.
Axitinib, a second-generation multi-targeted TKI against
VEGFR1, 2 and 3, is licensed in Europe for the treatment of
adult patients with mRCC after failure of Sunitinib or cytokines.
Efficacy is based on the AXIS trial which reported a longer
mPFS in Sunitinib pretreated patients of 6.5 months (95% CI
5.7–7.9 months) with a mOS of 15.2 months (95% CI 12.8–18.3
months). In our analysis, the mPFS was 5.83 months (95% CI
3.93–7.73 months) with mOS of 13.3 months (95% CI 8.6–17.9
months). These results are similar to the Axis trial and the
other real-life experiences (Vogl et al., 2013; Basso et al., 2014;
Maroto et al., 2014; Matias et al., 2014; Signorovitch et al.,
2015; Vogelzang et al., 2015, 2016; Guida et al., 2016; Hutson
et al., 2016; Laskey et al., 2016; Pal et al., 2016; Wagstaff et al.,
2016). The majority of the evaluated studies are retrospective
TABLE 4 | Multivariate adjusted Cox model.
Progression-free
survival (PFS) Overall survival (OS)
HR* (95% CI) p-value HR* (95% CI) p-value
NEFRECTOMY
Yes 0.32 (0.13–0.78) 0.01 0.24 (0.08–0.68) 0.007
PRIOR TREATMENT
(>13 months) 0.48 (0.25–0.94) 0.03 0.56 (0.24–1.30) 0.2
ORR
(RC + RP) 0.28 (0.10–0.77) 0.01 0.42 (0.12–1.48) 0.2
DCR
(RC + RP + SD) 0.35 (0.15–0.81) 0.01 0.36 (0.13–0.98) 0.047
HR, hazard ratio; 95% CI, 95% confidence interval.
*Multivariate Cox model adjusted for terms of age (continuous), gender, and center.
analysis of indirect comparison between standard second-line
treatments (Everolimus vs. Axitinib) and use Axitinib in second
or third line with the median duration of therapy as surrogate
of mPFS; others are available only in abstract form, therefore
not comparable. Evidences from randomized clinical trials,
retrospective studies or single-institution experiences do not
provide clear and conclusive information about the optimal
sequencing of TTs, furthermore, there is no patients stratification
based on prognostic criteria as in first-line. The IMDC model
(Heng score) was recently validated in second-line setting
resulting more reliable when compared with the three-factor
MSKCC model (Heng et al., 2014; Ko et al., 2015). In our
retrospective study, when the patients were stratified by Heng
score, mPFS was 5.73, 5.83, 10.03 months according to poor,
intermediate and favorable risk group, respectively. To date,
sequential treatment with VEGF-TKIs or mTORi, represents the
standard of care (Chowdhury et al., 2008; Facchini et al., 2009;
Calvo et al., 2012; Rizzo et al., 2015; Ko et al., 2015; Linee guida1).
The use of EVE is supported by the RECORD-1 trial though the
population was not homogeneous for line of treatment (patients
who have had two or more prior therapies were also included)
and the RECORD-4, a phase II trial, including only patients
in the second-line setting, confirmed the efficacy of EVE after
SUN or other first-line therapies (Motzer et al., 2008; Motzer R.
et al., 2015). The RECORD-4 mPFS was 5.7 months (95% CI
3.7–11.3) with previous Sunitinib, ORR was 7% (95% CI 2–17)
and OS 23.8 months (95% CI 13.7-NE; Table 5). The activity of
the sequence VEGF-TKI–VEGF-TKI has been demonstrated by
several trials showing a longer statistically significant mPFS and
in some mOS too (Rini et al., 2011; Motzer et al., 2013; Motzer
R. et al., 2015; Hutson et al., 2014; Eichelberg et al., 2015). A
network meta-analysis conducted by Leung et al. suggested that
axitinib is a more suitable TT option, compared to sorafenib
1Linee guida. Linee guida AIOM. Available online at: www.aiom.it
FIGURE 4 | Axitinib response rate (%).
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TABLE 5 | Comparison of mPFS, mOS, and tumor response between
RECORD 4 and SAX population.
RECORD 4 (n = 58) SAX (n = 62)
mPFS (mo) 5.7 5.83
mOS (mo) 23.8 13.3
DCR (%) 41 71
ORR (%) 7 25
Best overall response (%)
RC 1 2
PR 4 23
SD 37 47
PD 15 29
n, number of patients; CR, complete response; PR, partial response; SD, stable disease;
PD, progressive disease; ORR, overall response rate; DCR, disease control rate.
and pazopanib, after failure of first line treatment; Sunitinib
and Axitinib seem associated with a superior clinical benefit
when compared to Sorafenib, Pazopanib, and Temsirolimus;
in particular Axitinib is associated with the lowest risk of
withdrawal due to adverse events (Leung et al., 2014). Our
analysis confirms these results. Many clinicians choose second-
line TTs based on response to first-line therapy and depth of
remission. Escudier et al. (2014) conducted a post hoc analysis
of AXIS trial to evaluate the efficacy of Axitinib and Sorafenib
by response to prior therapy, duration of prior therapy, and
tumor burden in patients previously treated with Sunitinib or
cytokines. In regards to the prior therapy response, they did
not found statistically significant differences in PFS or OS in
responders vs. non-responders. In regards to duration of prior
therapy with Sunitinib, defined as shorter (<median) vs. longer
(≥median), they detected a significantly longer PFS with second-
line Axitinib only in patients who had received a longer prior
cytokines treatment (no relationship in patients treated with
Sunitinib neither in ones who had Sorafenib in second line);
OS with second-line Axitinib or Sorafenib was significantly
longer in patients who received longer prior therapy, except
in those treated with Sunitinib followed by Axitinib (Escudier
et al., 2014). On the contrary our analysis showed that, when
stratified patients by subgroups defined by duration of prior
therapy with Sunitinib (≤ vs. >median duration), there was
a statistically significant difference in mPFS with 8.9 (95% CI
4.39–13.40 months, p = 0.03) vs. 5.46 months (95% CI 4.04–
6.88 months, p = 0.03) for patients with a median duration
of Sunitinib >13.2 months, without differences in mOS. DCR
and ORR to previous Sunitinib treatment was associated with
longer statistically mPFS, 7.23 and 8.67 vs. 2.97 and 2.97 months,
respectively. mOS was not reached for ORR (RC+RP), the mean
OS according to DCR and ORR was 14.95 and 15.66 vs. 7.4
and 7.42 months, respectively. Our results are consistent with
those of Elaidi et al. who conducted a retrospective analysis
of 241 m-ccRCC patients who received a first-line TKI for ≥6
months followed by a second-line TKI or mTORi, showing
that patients who remained on first-line TKI between 11 and
22 months benefited from a TKI rechallenge rather than from
second-line mTORi (PFS [HR≈0.5; median PFS (months): 9.4
(5.9–12.2) vs. 3.9 (3.0–5.5), p = 0.003; TTF(months): 8.0 (5.5–
11.0) vs. 3.6 (3.0–4.6), p= 0.009]; Elaidi et al., 2015). Historically,
VEGF-targeted therapy was reported to achieve higher ORR
(20–30%) compared to mTOR-targeted therapy (≤10%), which
is supported by our analysis (Grünwald et al., 2015). The lack
of response to a VEGF-targeted agent in the first-line setting
does not preclude positive clinical outcomes with a second-
line VEGF-targeted agents. Prior nephrectomy correlated with
longer statistically mPFS (p = 0.01) and mOS (p = 0.003).
Overall Axitinib at standard schedule of 5mg bid, was well-
tolerated, with no grade 4 toxicity. The most common adverse
events of all grades were fatig (25.6%), gastro-intestinal disorders
(25.9%), hypertension (22.6%), and hypothyroidism (16.1%).
Our data showed a lower incidence of AEs than AXIS trial.
According to AEs recorded, we did not find predictor of better
outcome, unlike the AXIS analysis showed that patients who
developed diastolic blood pressure ≥90 mmHg or systolic below
140 mmHg within the first 8 or 12 weeks of randomization had
longer mOS. Dose escalation to 7 or 10mg bid was feasible in
15 patients (24.2%), without statistically significant differences
in terms of both mPFS and OS. Dose titration was well-
tolerated with only increase in the incidence of hypothyroidism
and fatig, no worsening of hypertension. It was interesting
to note that the 19.3% (12/62) of patients enrolled in our
analysis used a modified schedule of Sunitinib (2 w on 1 w
off) in first line treatment without differences in terms of
outcomes. These results, although on a small size population,
confirm those of several retrospective study that evaluated
Sunitinib administered on alternative schedules with reduction
in the AEs and achieving comparable outcomes to the standard
schedule (Atkinson et al., 2014; Bracarda et al., 2015; Lee
et al., 2015). Our analysis confirm that sequence TKI-TKI
(Sunitinib–Axitinib) was well-tolerated without worsening in
side effects, with a mOS for the overall analysis population of
34.7 months (95% CI 18.4–51.0 months), consistent with those
of the AXIS trial (33.7 months, 95%CI 28.6–36.96 months).
Recently were published the results of CheckMate 025 in which
Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor,
was associated with longer mOS, 25.0 months (95% confidence
interval [CI], 21.8 to not estimable) vs. 19.6 months (95% CI,
17.6 to 23.1) with everolimus, in previous treated mRCC patients
with one or two regimens of anti-angiogenic therapy. It will be
interesting to evaluate the efficacy of nivolumab vs. VEGFRi,
such as axitinib in second pure line of treatment and their
sequencing (Motzer R. J. et al., 2015).
CONCLUSIONS
Our results are consistent with the available literature; this
retrospective analysis confirms the efficacy and safety of
Axitinib in an unselected population. DCR, ORR, duration
of prior therapy with Sunitinib, and prior nephrectomy may
represent prognostic factor of a longer mPFS with Axitinib
while only DCR and prior nephrectomy correlated with a
longer mOS.
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